1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

GTX to purchase CytoCare, Inc.

Discussion in 'GTX' started by Anonymous, May 20, 2010 at 10:38 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Is this rumor true? I heard that they wanted to expand their cancer line since their Urology product was delayed (give the reps something addtional to sell and generate more revenue).
     

  2. Anonymous

    Anonymous Guest

    first all the sales reps were let go so they have none. That being said it is interesting that PH had a few huge amts of stock acquired recently. Maybe the stock price will take a jump?
     
  3. Anonymous

    Anonymous Guest

    I heard that they had a few RM/DMs selling the breast cancer product.
     
  4. Anonymous

    Anonymous Guest

    Re: GTX to purchase CytoCore, Inc.

    They may need to acquire products until their pipeline products are approved. Cyto Core would be interesting. Neomartix's HALO would be more fun.
     
  5. Anonymous

    Anonymous Guest

    CytoCare is a better fit.
     
  6. Anonymous

    Anonymous Guest

    Has anyone heard how Chris West is doing? Is he still working?
     
  7. Anonymous

    Anonymous Guest

    Very true.
     
  8. Anonymous

    Anonymous Guest

    Breast cancer product is a dog.